Overview

Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breast cancer who were previously treated with an anthracycline and a taxane.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Capecitabine